rates remaining suboptimal, and success rates decreasing progressively from 50% in MDR-TB cases to 40% in XDR-TB cases and less than 20% in cases with resistance patterns beyond XDR-TB. 2, 3, 13, 14 Following more than 40 years of neglect since the launch on the market of the last TB-specific drug (rifampicin), the available armamentarium of anti-TB drugs currently includes two new drugs (delamanid and bedaquiline) and a few repurposed compounds. 9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] As clinical experience with these new drugs and some of the repurposed drugs is still limited, and the number of drugs for which susceptibility is confirmed is often very limited, [20] [21] [22] clinicians face more and more difficulties in designing effective regimens as per WHO guidelines. 16 Recent evidence suggests that a 9 to 12-month regimen (known as the 'Bangladesh regimen') may be effective in treating MDR-TB cases (Table 1) . [26] [27] [28] As part of the ALAT/ERS LATSINTB project (a research coordination project), the present article describes the rationale for the introduction of the Bangladesh or 'shorter regimen' to treat MDR-TB, the principles of the new 2016 WHO recommendations, and the main operational issues related to their implementation under programmatic conditions in high MDR-TB prevalence settings.
Rationale for the shorter regimen and the new WHO guidelines
The rational composition of this new regimen is similar to that of the traditional 24-month one, with a consistent number of drugs and the inclusion of a fluoroquinolone, a second-line injectable drug, and two other 'companion' drugs (e.g., drugs supporting the core drugs to prevent the selection of drug-resistant mutants). 13, 15, 16 However, in the new regimen moxifloxacin is 'the' fluoroquinolone, while clofazimine replaces cycloserine. The Bangladesh regimen includes an initial phase of 4 to 6 months of kanamycin, gatifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid, and ethambutol, followed by 5 months of gatifloxacin, clofazimine, pyrazinamide, and ethambutol. 13, 14, 16 Based on the available evidence, the WHO has recommended this shorter MDR-TB regimen in its new 2016 MDR-TB guidelines, with moxifloxacin replacing gatifloxacin (originally used in the Bangladesh regimen).
The new regimen, which is much cheaper than longer ones (<1000 dollars), 8, 16 is indicated only for ''adults and children with rifampicin-resistant and MDR-TB who have not been previously treated with second-line drugs and in whom resistance to fluoroquinolones and second-line injectable agents have been excluded or considered highly unlikely''. 16 The indication also includes people living with HIV/AIDS. 16 A summary of the composition of the regimen and a list of the recommended exclusion criteria for the shorter TB regimen in favour of the longer regimen are given in Table 2 .
The same WHO guidelines recommend a diagnostic tool designed to speed up the detection of TB resistance -the rapid molecular MTBDRsl test. 16 The promotion of broader and quicker molecular testing will ensure the appropriate selection of patients who will benefit from the shorter MDR-TB regimen, while reducing the 'infectious period' and the subsequent transmission of resistant strains of Mycobacterium tuberculosis within the community. Furthermore, the rapid initiation of an adequate regimen will minimize the possible development of additional drug resistance ('super-resistance'), which is among the criteria defining 'treatment failure' in the 2015 WHO definitions. 
Operational issues and evidence of eligibility for the shorter regimen
This is a concrete demonstration of the genuine efforts being made to provide wider access to quality MDR-TB diagnostic and treatment services in high MDR-TB prevalence countries. Following the endorsement of the shorter MDR-TB regimen, clinicians and public health experts have started posing three questions:
(1) Under programmatic conditions, what is the proportion of patients who might not be eligible for the shorter regimen in reference centres or settings concentrating on difficult-to-treat MDR-TB cases (e.g., those exposed to several previous rounds of treatment or with previous treatment failure)? In other words, what proportion of cases will be eligible for treatment with the shorter MDR-TB regimen in programmatic (non research) settings? (2) In countries or settings with sub-optimal laboratory services, will it be possible to use the shorter regimen based on epidemiological surveillance data or periodic drug resistance surveys? (3) In the case of resistance to one or two of the drugs in the regimen, can compromised drugs be substituted in order to maintain the efficacy of the regimen, and if so, to what extent?
In summary, the regimen is for MDR-TB cases not previously treated with second-line anti-TB drugs and, therefore, should not be used in the case of (a) previous use of any of the Bangladesh regimen drugs, and (b) documented or suspected resistance to one or more of them. 16 Initial evidence is available only for the first question. A recent multi-centre, observational, retrospective, cohort study of the International Carbapenems Study Group (ICSG) was conducted in reference MDR-TB centres in Europe (eight countries) and Latin America (three countries). 13, 14 All of the drugs in the Bangladesh regimen were routinely tested in the participating centres, except high-dose isoniazid and clofazimine. The study found that only 14 out of 348 adult patients (4.0%) were susceptible to all of the drugs, and were therefore potentially suitable for the 'shorter regimen'. 13 Interestingly, the prevalence of resistance to the firstline drugs in the regimen (ethambutol and pyrazinamide) exceeded 60% and that of prothionamide exceeded 50%. Furthermore, the proportion of resistance to the two most important pillars of the regimen -quinolones and kanamycin -exceeded 40%.
The prevalence of resistance to these two drugs was higher in Latin American than in Europe. The authors concluded that the shorter MDR-TB regimen ''would have an impact on only minority of patients and may have limited use in these settings where patients have more resistant forms of TB and are more treatment experienced (like in reference centres)''. However, the limited sample size, non-representativeness of the data with the possibility of selection bias, and the limited reliability of drug susceptibility testing to pyrazinamide and ethambutol (even when performed in quality assured laboratories) should be considered when interpreting the results of that study. In addition, no reliable drug susceptibility testing is yet available for clofazimine and ethionamide. 13 This study confirmed the results of previous non-representative cohorts that identified prevalence rates around 30% for fluoroquinolones, 60% for ethambutol, 70% for pyrazinamide, 45% for prothionamide and were not designed to evaluate the Bangladesh regimen, they did not provide information on how many patients would potentially have benefitted from the regimen. A final comment is that we need more information on the suitability of patients for high-dose isoniazid. The existing evidence suggests that high-dose isoniazid is effective in the presence of the inhA gene mutation and in absence of the katG mutation. This combination is estimated to be present in no more than 12% of patients globally, with lower values in Africa.
The answer to question 2 is not available, and it is the authors' opinion that caution is needed in assuming that no drug resistance exists in low MDR-TB prevalence settings; testing all cases is the best option.
As far as question 3 is concerned, it is likely that kanamycin will be replaced by capreomycin or amikacin, although these modifications will increase the cost of the regimen. 13 It is also possible that, in view of resistance to one or more drugs in the regimen, clinicians might decide to replace them with the new drugs (delamanid, bedaquiline) or with the most effective repurposed drug (although more prone to adverse events), e.g. linezolid. It is important to underline that these changes are not recommended, as no evidence currently exists regarding the possibility of modifying the regimen with these drugs while keeping the short duration profile (and ensuring tolerability, efficacy, and adherence). 13 
Conclusions
In conclusion, a shorter, cheaper, and well-tolerated MDR-TB regimen is likely to impact the number of patients treated and improve adherence. 13, 14 The preliminary evidence available on the country-or setting-specific prevalence of resistance to the drugs in the regimen needs to be expanded, taking into account that high combined resistance to fluoroquinolones and pyrazinamide might represent the main limitation to the success of the new regimen. A core factor in facilitating the appropriate use of the new regimen will be the systematic use of rapid MTBDRsl testing, so that the regimen is prescribed to the correct patients.
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The increasing possibility of dosing blood levels of the different drugs through therapeutic drug monitoring (TDM) will further improve the tolerability of the shorter regimen (as well as that of the longer one) in the coming future, while increasing treatment adherence.
Importantly, the role of expert discussion (cohort discussion and 'consilia') to support clinical decisions in difficult-to-treat cases needs, once more, to be emphasized. 
